Whilst others found high SLFN11 gene expression associates with better prognosis in cisplatin-treated ovarian cancer patients [5], we could not confidently determine if SLFN11 associated with improved prognosis to the standard of care carboplatin–paclitaxel doublet, but trends indicated longer PFI in SLFN11 high patients. Here, SLFN11 is linked to ovarian cancer.